Dive Into Dollar Tr...
Health Care: Drugs
Arena Pharmaceuticals Inc. (ARNA: NASDAQ)
$7.98 -0.02 | -0.25%
05/17/13 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 125.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 0.17 | 0.63 | 0.98 |
| Price to Sales (TTM) | 62.58 | 7.02 | 1.42 |
| Price to Book (MRQ) | 21.61 | 6.47 | 2.41 |
| Price to Tangible Book (MRQ) | 24.70 | 14.29 | 5.08 |
| Price to Cash Flow (TTM) | -25.90 | 41.70 | 9.80 |
| Price to Free Cash Flow (TTM) | -40.60 | 139.40 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.40 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.30 |
| Dividend 5 Yr Growth Rate (%) | n.a. | 5.57 | 2.80 |
| Payout Ratio (TTM) | 0.00 | 34.00 | 37.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 8.40 | 25.00 | 0.30 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 116.90 | 35.70 | 2.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 14.05 | 11.34 | 3.62 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 17.70 | 99.90 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 17.70 | 99.90 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | 8.12 |
| Capital Spending - 5 Yr Growth Rate (%) | -50.14 | 14.10 | 3.83 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 5.10 | 2.60 | 1.10 |
| Current Ratio (MRQ) | 5.50 | 3.40 | 1.60 |
| LT Debt to Equity (MRQ) | 0.90 | 0.64 | 0.73 |
| Total Debt to Equity (MRQ) | 0.92 | 0.69 | 0.86 |
| Interest Coverage (TTM) | n.a. | 4.60 | 6.70 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 82.00 | 80.70 | 47.80 |
| Gross Margin - 5 Yr Avg | 71.60 | 82.90 | 47.00 |
| EBITD Margin (TTM) | n.a. | 22.00 | 19.50 |
| EBITD - 5 Yr Avg | -505.01 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 11.60 | 11.70 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 13.40 | 10.20 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | 0.00 | 0.08 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 7.40 | 6.30 |
| Return on Assets (TTM) | -32.90 | 4.20 | 3.20 |
| Return on Assets - 5 Yr Avg | -61.10 | 3.10 | 2.30 |
| Return on Investment (TTM) | -50.00 | 5.40 | 8.50 |
| Return on Investment - 5 Yr Avg | -84.20 | 4.10 | 5.90 |
| Efficiency | |||
| Revenue/Employee (TTM) | 94,782.00 | n.a. | n.a. |
| Net Income/Employee (TTM) | -265,447.00 | n.a. | n.a. |
| Receivable Turnover (TTM) | 22.30 | 6.00 | 7.90 |
| Inventory Turnover (TTM) | 1.40 | 1.80 | 7.70 |
| Asset Turnover (TTM) | 0.10 | 0.50 | 0.40 |
Portfolios with ARNA
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Under-$10 Moving Hig...
- UserMy Watch List
- Usermichelle
- User2012 picks 10/28/20121
- Usermine
- ContributorStocks Under-$10 Moving Hig...
- UserMy SP portfolio
- UserMyfuture
- ContributorStocks Under-$10 Setting Up...
Latest ARNA Headlines from TheStreet
- Biotech Stock Mailbag: Exact Sciences, Galena, Titan, Arena, Breakthrough Therapy 04.12.13 | 06:04 am
- Large Vivus Shareholder Seeks More Change 04.10.13 | 10:04 am
- Arena Bulls, Bears Endure Annoyingly Long Wait for Belviq Launch 04.10.13 | 09:04 am
- Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
- Vivus Piles New Debt On Top Of Excuses 03.26.13 | 10:03 am
- Arena Pharmaceuticals Inc. (ARNA): Health Care's Featured Stock Of The Day 03.25.13 | 05:03 pm
- 2 Drug Stocks Under $10 To Pick As Favorites 03.25.13 | 02:03 pm
- Best And Worst FDA Drug Approval Stocks of 2013 03.12.13 | 08:03 am
- Play TheStreet's FDA Drug Approval Contest 03.05.13 | 12:03 pm
- Top 10 Trending On StockTwits At The Close (March 4) 03.04.13 | 06:03 pm
Press Releases for ARNA
- Pill Economics - Research Report On Arena Pharmaceuticals, Inc. And Amgen, Inc. - PR Newswire 01.23.13 | 08:01 am
- Stock Alerts For Coca-Cola, Deere, News Corp., Arena Pharmaceuticals, And American Tower Released By InvestorsObserver - PR Newswire 06.28.12 | 09:06 am
- Arena Pharmaceuticals Investigated By Goldfarb Branham Law Firm LLP - Business Wire 10.08.10 | 09:10 am
- Girard Gibbs LLP Files Class Action Lawsuit Against Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) - Business Wire 09.29.10 | 05:09 pm
- Lieff Cabraser Heimann & Bernstein, LLP Announces Class Action Lawsuits Against Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) - Business Wire 09.28.10 | 02:09 pm
- Investor Notice: The Rosen Law Firm Announces Filing Of Securities Class Action Against Arena Pharmaceuticals, Inc. - ARNA - Business Wire 09.22.10 | 06:09 pm
- Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Arena Pharmaceuticals, Inc. - Business Wire 09.22.10 | 05:09 pm
- The Law Office Of Robbins Umeda LLP Announces An Investigation Of Arena Pharmaceuticals, Inc. - Business Wire 09.22.10 | 12:09 pm
Partner Headlines for ARNA
- 4 Healthcare Stock Stories Prescribed for Investors - Wall St. Cheat Sheet 04.01.13 | 05:04 am
- 4 Healthcare Stock Stories Prescribed for Investors - Wall St. Cheat Sheet 04.01.13 | 05:04 am
- Fannie Mae And Freddie Mac, Short-Term Trade Or Deep Value Investment? - Seeking Alpha 03.25.13 | 09:03 am
- A Look At 3 Obesity Stocks - Seeking Alpha 03.05.13 | 09:03 am
- Trius Therapeutics: New MSRA Treatment Could Bring Billions In Revenues - Seeking Alpha 03.05.13 | 09:03 am
- Pre-Market Earnings Report for March 4, 2013 : RIG, SSYS, TECD, ARNA, CEL, BYD, YGE, ALVR - NASDAQ 03.01.13 | 09:03 pm
- Arena's Recent Outperform Call And A Probability Weighted Valuation - Seeking Alpha 02.08.13 | 08:02 am
- Arena Must Wait For European Approval - Seeking Alpha 01.19.13 | 07:01 am
- Orexigen: The Best Bet In Obesity For 2013 - Seeking Alpha 12.17.12 | 09:12 am
- Arena Opening New Doors - Seeking Alpha 11.29.12 | 09:11 am
